Camden Capital, LLC Biomarin Pharmaceutical Inc Transaction History

Camden Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $199,970 - $236,214	2,386 New	2,386 $208,000
Q3 2023 Nov 03, 2023	BUY	$85.07 - $94.48 $195,320 - $216,926	2,296 New	2,296 $203,000
Q1 2023 May 11, 2023	BUY	$87.74 - $117.27 $7,282 - $9,733	83 Added 3.29%	2,603 $253,000
Q4 2022 Feb 13, 2023	SELL	$80.93 - $108.63 $396,880 - $532,721	-4,904 Reduced 66.06%	2,520 $260,000
Q3 2022 Nov 08, 2022	BUY	$82.16 - $96.94 $345,647 - $407,826	4,207 Added 130.77%	7,424 $629,000
Q2 2022 Aug 03, 2022	SELL	$71.48 - $86.85 $48,177 - $58,536	-674 Reduced 17.32%	3,217 $267,000
Q1 2022 May 06, 2022	BUY	$74.28 - $92.69 $57,047 - $71,185	768 Added 24.59%	3,891 $300,000
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $35,429 - $45,186	494 Added 18.79%	3,123 $276,000
Q3 2021 Nov 03, 2021	BUY	$74.77 - $85.47 $196,570 - $224,700	2,629 New	2,629 $203,000
Q2 2020 Aug 11, 2020	SELL	$79.55 - $124.22 $254,560 - $397,504	-3,200 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$64.27 - $86.37 $205,664 - $276,384	3,200 New	3,200 $271,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Camden Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Camden Capital, LLC with notifications on news.